| Returns | 1W : -2.6% , 1M : -0.7%,1Y : 13.8% |
| LT : |
Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : Low |
| ST : |
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
| Peers & Returns | 1W | 1M | 1Y |
| LINCOLN PHARMACEUTICALS LTD | -2.6% | -0.7% | 13.8% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | -1.1% | 0.1% | 30.6% |
| DR REDDYS LABORATORIES LTD | -0.4% | -3.6% | 65.1% |
| DIVIS LABORATORIES LTD | -0.6% | -3.9% | 94.4% |
| CIPLA LTD | 0.8% | -2% | 72.3% |
| BIOCON LTD | -12.3% | -18.6% | 51% |
| AUROBINDO PHARMA LTD | 0.8% | 3.8% | 81.4% |
| LUPIN LTD | 1.6% | 12.1% | 44.7% |
| TORRENT PHARMACEUTICALS LTD | 2.1% | -3.9% | 37% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
9.04
P/E Calculated based on EPS of 24.78
[ Mar2020 - Standalone Results ] 1.47
P/B Calculated based on Book Value of 152.25
[ Mar2020 - Standalone Results ] 1.17
P/S Calculated based on Revenues of 382.532 Cr
[ TTM - Standalone Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
-6% -15% -2% |
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
